CING

Cingulate is a single-asset, clinical-stage biopharma with zero product revenue across its entire history (net losses every year: -$20.7M FY21, -$17.7M FY22, -$23.5M FY23, -$16.6M FY24, -$22.4M FY25) and an accumulated deficit of $132.4M against just $2.51M of stockholders' equity. The 10-K carries an explicit going-concern qualification: management states there is 'substantial doubt about the Company's ability to continue as a going concern within one year,' and that cash of $11.0M will only 'satisfy our capital needs late into the fourth quarter of 2026.' With operating cash flow of -$17.2M in FY2025, the runway is short and another raise is not optional — it is required, on terms that 'may not be available to us on acceptable terms, or at all.'

The entire equity is a wager on CTx-1301, an ADHD candidate whose NDA carried a PDUFA target action date of May 31, 2026. The provided filings (10-K dated 2026-03-18, 10-Q period 2026-03-31) all predate that date, so the outcome is not in the data — meaning the single most decisive fact for the thesis is unknowable from what's provided. The filing itself flags this dependence: 'If we are unable to secure approval of CTx-1301... our ability to create stockholder value will be severely limited.' That is the textbook definition of un-investable binary risk.